Phase 3 Trial of Cabozantinib to Treat Advanced Neuroendocrine Tumors is a research paper published in New England Journal of Medicine (2024). On theSindex it has a DataRank of 3.0. It has been cited 141 times, with 100 citing works in its 1-hop citation network.
Scored on demand from live citation data
Linked data & code
Repositories this paper deposited data in (declared in PubMed).
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.743
From this paper's citation signal
Citation Network Contribution
2.2
From 61 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 100 citers.
National Cancer Institute
Grant: U10CA180820
National Cancer Institute
Grant: U10CA180821 and U10CA180882
National Cancer Institute
Grant: U10CA180868
National Cancer Institute
Grant: U10CA180888
National Cancer Institute
Grant: UG1CA189856, UG1CA232760, UG1CA233180, UG1CA233290
National Cancer Institute
Grant: UG1CA233329, UG1CA233331
NCI NIH HHS
Grant: U10 CA180821
NCI NIH HHS
Grant: U10 CA180882
NCI NIH HHS
Grant: UG1 CA232760
NCI NIH HHS
Grant: UG1 CA233180
NCI NIH HHS
Grant: UG1 CA189804
NCI NIH HHS
Grant: UG1 CA189856
NCI NIH HHS
Grant: UG1 CA233329
NCI NIH HHS
Grant: UG1 CA233331
NCI NIH HHS
Grant: UG1 CA233290
NCI NIH HHS
Grant: P30 CA008748
Exelixis
FWCI
41.14
Citation Percentile
1.0%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals